1) Strong Financial Performance and Guidance Update
- Q3 2026 revenue reached nearly $7 billion compared to Q3 2025, with a 39% year-over-year growth.
- Key product revenue increased by over $6 billion, driven by oncology, immunology, and neuroscience portfolios, which doubled in revenue.
- Non-GAAP earnings per share were $7.48, up from $7.20 in Q3 2025.
- Full year revenue guidance raised to $91-$92 billion, reflecting strong performance and market uptake.
- Non-GAAP performance margin expected to be between 52.5% and 54.2%.

2) Pipeline Advancements and Regulatory Approvals
- Significant regulatory milestones achieved, including US approvals for a new weekly insulin and new indications for Inluriyo, Jaypirca, and Mounjaro.
- The GLP-1 bridge program expanded access to obesity medicines for approximately 20 million seniors in the US, with over half a million prescriptions filled since launch.
- New acquisitions (AtaiBeckley and Merida Biosciences) enhance the pipeline, focusing on neuroplasticity and precision immunology therapies.
- Upcoming R&D Day on December 7 will provide further insights into pipeline developments.

3) Market Dynamics and Competitive Landscape
- The incretin market is expanding, with Mounjaro and Zepbound generating over $16 billion in revenue, indicating a strong market presence.
- The US revenue growth was primarily driven by volume, with a 34% increase, despite a 7% decline in price.
- International markets showed robust growth, particularly in China (62% growth) and the rest of the world (87% growth).
- Foundayo's launch is progressing well, with expectations for regulatory approval in type 2 diabetes in Q4 2026.

4) Operational Investments and Future Outlook
- Lilly is investing in manufacturing capabilities with new facilities in Houston and Richmond, totaling $11.5 billion.
- The company aims to reach resource-limited settings with its obesity initiative by 2040.
- Guidance for 2027 suggests continued growth in the incretin market, with expectations for sustained volume growth and new product launches.
- Pricing pressures are anticipated, but overall access improvements are expected to stabilize commercial pricing.

5) Leadership Changes and Strategic Focus
- Patrik Jonsson, president of Lilly International, will retire at the end of 2026, with Ilya Yuffa taking on expanded responsibilities.
- The leadership transition is part of Lilly's strategic focus on global markets and enhancing operational capabilities.
- The call did not provide detailed insights into specific future product launches or additional pipeline candidates beyond those already mentioned.

Bottom line: Eli Lilly's strong Q3 performance and raised guidance reflect robust growth in its key product lines and successful pipeline advancements. The company's strategic investments and market expansion initiatives position it well for sustained long-term growth, making it an attractive prospect for shareholders.